VCYT

+ Watchlist + Portfolio

Veracyte, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $42.19
52-Week Range: $28.25 – $60.91
Market Cap: $3.36B
P/E (TTM): 29.85
EPS (TTM): 1.40
Dividend Yield: —

Advanced Metrics

Price/Book: 2.42
PEG Ratio: —
Return on Equity: 8.77%
Return on Assets: 4.09%
Gross Margin: 73.76%
Operating Margin: 15.29%
Profit Margin: 20.37%
Current Ratio: 9.16
Debt/Equity: 0.03
Total Debt: $40.11M
Free Cash Flow: $106.23M
Revenue Growth: 15.50%
Earnings Growth: —
Enterprise Value: $2.95B

VCYT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$296.54M	$361.05M	$445.76M	$517.14M
Cost of Revenue	$120.86M	$131.37M	$147.62M	$154.61M
Gross Profit	$175.68M	$229.68M	$298.14M	$362.53M
Research & Development	$40.60M	$57.30M	$69.29M	$70.81M
Selling, General & Admin	$170.76M	$187.72M	$206.04M	$210.95M
Operating Expenses	$211.02M	$247.13M	$278.63M	$284.25M
Operating Income	-$35.34M	-$17.45M	$19.51M	$78.28M
EBITDA	-$10.30M	-$49.41M	$49.20M	$89.62M
Pretax Income	-$36.43M	-$76.61M	$25.74M	$68.20M
Income Tax	$133.00K	-$2.21M	$1.61M	$1.85M
Net Income	-$36.56M	-$74.40M	$24.14M	$66.35M
Diluted EPS	-0.51	-1.02	0.31	0.82
Diluted Shares	71.55M	72.64M	78.16M	80.57M

VCYT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$154.25M	$216.45M	$239.09M	$362.58M
Receivables	$44.02M	$40.38M	$46.52M	$44.66M
Inventory	$14.29M	$16.13M	$21.75M	$20.55M
Current Assets	$248.64M	$285.62M	$372.27M	$488.38M
Total Assets	$1.16B	$1.11B	$1.30B	$1.41B
Current Liabilities	$62.61M	$61.24M	$78.63M	$59.94M
Total Debt	$14.72M	$12.63M	$50.74M	$39.65M
Total Liabilities	$81.22M	$70.80M	$124.07M	$96.44M
Retained Earnings	-$393.72M	-$468.12M	-$443.98M	-$377.63M
Shareholders' Equity	$1.08B	$1.04B	$1.18B	$1.31B
Working Capital	$186.02M	$224.38M	$293.63M	$428.44M

VCYT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$7.54M	$44.22M	$75.10M	$136.31M
Capital Expenditure	-$8.55M	-$9.96M	-$11.29M	-$9.68M
Free Cash Flow	-$1.01M	$34.26M	$63.81M	$126.63M
Depreciation & Amortisation	$25.93M	$27.19M	$23.46M	$21.41M
Stock-Based Compensation	$26.73M	$33.14M	$36.25M	$43.60M
Investing Cash Flow	-$29.39M	$15.11M	-$56.27M	-$9.21M
Financing Cash Flow	$3.49M	$2.84M	$4.90M	-$4.22M
Net Change in Cash	-$18.36M	$62.17M	$23.73M	$122.88M

VCYT Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$130.16M	$131.87M	$140.64M	$139.07M	—
Cost of Revenue	$40.40M	$40.59M	$38.66M	$37.91M	—
Gross Profit	$89.77M	$91.28M	$101.97M	$101.16M	—
Research & Development	$16.26M	$15.98M	$20.85M	$27.10M	—
Selling, General & Admin	$57.61M	$50.71M	$43.47M	$50.84M	—
Operating Expenses	$75.46M	$68.17M	$62.06M	$78.51M	—
Operating Income	$14.31M	$23.11M	$39.91M	$22.65M	—
EBITDA	$6.74M	$24.16M	$45.93M	$35.40M	—
Pretax Income	$1.25M	$18.89M	$40.63M	$29.97M	—
Income Tax	$2.23M	-$248.00K	-$515.00K	$1.27M	—
Net Income	-$980.00K	$19.14M	$41.15M	$28.71M	—
Diluted EPS	-0.01	0.24	0.51	0.35	0.31
Diluted Shares	78.39M	79.69M	81.39M	81.31M	82.06M

VCYT Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$186.12M	$219.50M	$315.57M	$362.58M	$263.14M
Receivables	$53.78M	$50.81M	$47.83M	$44.66M	$50.11M
Inventory	$24.25M	$25.02M	$20.33M	$20.55M	$21.42M
Current Assets	$383.15M	$414.68M	$449.22M	$488.38M	$522.17M
Total Assets	$1.32B	$1.34B	$1.37B	$1.41B	$1.44B
Current Liabilities	$75.13M	$76.43M	$72.15M	$59.94M	$56.12M
Total Debt	$50.50M	$50.65M	$40.45M	$39.65M	$39.33M
Total Liabilities	$120.47M	$123.05M	$110.12M	$96.44M	$91.99M
Retained Earnings	-$436.94M	-$437.92M	-$418.78M	-$377.63M	-$348.92M
Shareholders' Equity	$1.19B	$1.22B	$1.26B	$1.31B	$1.34B
Working Capital	$308.03M	$338.25M	$377.07M	$428.44M	$466.06M

VCYT Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$5.36M	$33.60M	$44.76M	$52.58M	$35.22M
Capital Expenditure	-$1.82M	-$1.29M	-$2.79M	-$3.78M	-$2.96M
Free Cash Flow	$3.54M	$32.32M	$41.97M	$48.80M	$32.25M
Depreciation & Amortisation	$5.36M	$5.49M	$5.27M	$5.30M	$5.43M
Stock-Based Compensation	$10.96M	$10.98M	$10.76M	$10.90M	$12.76M
Investing Cash Flow	-$51.82M	-$224.00K	$48.26M	-$5.43M	-$127.96M
Financing Cash Flow	-$6.48M	-$566.00K	$2.98M	-$149.00K	-$6.63M
Net Change in Cash	-$52.94M	$32.81M	$96.00M	$47.00M	-$99.38M

Market Snapshot

About

Veracyte is a genomic diagnostics company that develops and commercializes molecular tests for cancer diagnosis. The company provides solutions for thyroid, lung, prostate, breast, and bladder cancers, helping physicians make treatment decisions. Its products include Afirma, Prosigna, Percepta, Envisia, and Decipher tests.